| Name | Title | Contact Details |
|---|
Liberty BioSecurity’s multi-disciplinary research teams transform life science discoveries into global-class, industry leading solutions.
Boston Biochem is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Allucent is a global biopharmaceutical services company founded in 2022 through the merger of several specialized providers. The company focuses on supporting small and mid-sized biotech firms in developing innovative treatments for patients with unmet medical needs. With over 30 years of combined experience, Allucent offers a range of services including regulatory consulting, clinical operations management, biometrics, and clinical pharmacology, particularly emphasizing oncology. Headquartered in Cary, North Carolina, Allucent has a strong global presence with offices in North America, Europe, Central/Eastern Europe, and Asia/Middle East. The company has conducted more than 825 clinical trials across over 70 countries, showcasing its extensive operational expertise. Allucent is dedicated to helping clients navigate the complexities of drug development and regulatory approval, ultimately accelerating the delivery of breakthrough therapies to patients.
Kawasumi Laboratories America is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.